Abstract
Purpose/Objective: To update the results of a phase II trial that was undertaken to assess the toxicity, local-regional (LR) control, and survival of the combination of accelerated fractionation by concomitant boost (AFX-CB) and concurrent cisplatin for the treatment of patients with locally advanced head and neck carcinomas (HNC).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
